October 28, 2010 - Coronary stent manufacturer Stentys is now listed and traded on the NYSE Euronext Paris (Ticker: STNT). As a result of the IPO, the company has raised $31.9 million, which will be used to commercialize its stents in Europe and obtain regulatory approvals in the United States.
"The clinical evidence is indisputable: malapposition, which is a known cause of early stent thrombosis and repeat AMI, can be eliminated with the use of a self-apposing stent," said Gonzague Issenmann, CEO and cofounder of Stentys.
Stentys received the CE Mark in 2010 for its self-apposing stents. The stents adapt to the anatomic changes of the arteries in the post-infarction phase, preventing the malapposition problems associated with conventional stents.
For more information: www.stentys.com